胶质瘤患者神经心理功能、APOE与淀粉样蛋白成像的初步研究
该初步研究纳入20例接受适形放疗±化疗的胶质瘤患者(6例APOE ε-4携带者,14例非携带者),在平均5年(SD=0.83)后复评神经心理功能并行18F-florbetaben PET。结果显示注意力显著下降(Brief Test of Attention,p=0.018),APOE ε-4携带者注意力/工作记忆随时间显著下降(WAIS-III数字顺背p=0.028,数字倒背p=0.032),但FBB PET各分析在两组间无显著差异。
要点
- 胶质瘤患者放疗后数年注意力显著下降(p=0.018)。
- APOE ε-4携带者注意力/工作记忆随时间显著下降。
- FBB PET分析在APOE ε-4携带者与非携带者间无显著差异。
核心结论
- 胶质瘤患者可能在治疗数年后出现注意力和执行功能恶化,APOE ε-4等位基因可能调节认知下降,但不依赖β-淀粉样蛋白沉积增加。
研究设计与样本
- 初步研究,纳入20例接受适形放疗±化疗的胶质瘤患者,其中6例APOE ε-4携带者、14例非携带者,完成神经心理复评(平均间隔5年,SD=0.83)及脑MRI和FBB PET扫描。
主要发现
- 既往与当前神经心理评估比较,注意力显著下降(Brief Test of Attention,p=0.018),言语学习接近显著下降(Hopkins Verbal Learning Test-Learning,p=0.07)。
- 按APOE状态比较,注意力/工作记忆随时间变化显著(WAIS-III数字顺背p=0.028,数字倒背p=0.032),APOE ε-4携带者出现下降。
- FBB PET各分析在APOE ε-4携带者与非携带者间均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Brain tumor patients treated with radiotherapy (RT) often develop cognitive dysfunction, and recent studies suggest that the APOE ε-4 allele may influence cognitive outcome. The ε-4 allele is known to promote beta (β) amyloid deposition in the cortex, and preliminary evidence suggests that RT may be associated with this process. However, it is unknown whether β-amyloid accumulation contributes to treatment neurotoxicity. In this pilot study, we assessed neuropsychological functions and β-amyloid retention using 18F-florbetaben (FBB) PET in a subset of brain tumor patients who participated in our study of APOE polymorphisms and cognitive functions. Twenty glioma patients treated with conformal RT ± chemotherapy participated in the study: 6 were APOE ε-4 carriers and 14 were non-ε-4 carriers. Patients completed a neuropsychological re-evaluation (mean time interval = 5 years, SD = 0.83) and brain MRI and FBB PET scans. Wilcoxon signed-rank test comparisons between prior and current neuropsychological assessments showed a significant decline in attention (Brief Test of Attention, p = 0.018), and a near significant decline in verbal learning (Hopkins Verbal learning Test-Learning, p = 0.07). Comparisons by APOE status showed significant differences over time in attention/working memory (WAIS-III digits forward, p = 0.028 and digits backward, p = 0.032), with a decline among APOE ε-4 carriers. There were no significant differences in any of the FBB PET analyses between APOE ε-4 carriers and non-ε-4 carriers. The findings suggest that glioma patients may experience worsening in attention and executive functions several years after treatment, and that the APOE ε-4 allele may modulate cognitive decline, but independent of increased β-amyloid deposition.
引用
- Correa DD, Kryza-Lacombe M, Zhou X, et al. A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas. J Neurooncol. 2017. PMID: 29168082. doi:10.1007/s11060-017-2692-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。